IGC Pharma (IGC) Change in Account Payables (2010 - 2025)
IGC Pharma (IGC) posted quarterly Change in Account Payables of -$303000.0 for Q3 2025, down 15050.0% year-over-year from N/an in Q3 2024, and down 694.12% quarter-over-quarter from $51000.0 in Q2 2025.
IGC Pharma (IGC) Change in Account Payables (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Change in Account Payables for 16 consecutive years, with -$303000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Change in Account Payables fell 15050.0% year-over-year to -$303000.0; the TTM figure through Sep 2025 stood at -$141000.0 (down 164.09% YoY), while the FY2026 annual figure was $241000.0, up 127.36% from the prior year.
- Change in Account Payables eased to -$303000.0 in Q3 2025 per IGC's latest filing, from $51000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $773000.0 in Q1 2021 and bottomed at -$613000.0 in Q4 2021.
- Historically, Change in Account Payables has averaged $15315.8 across 5 years, with a median of $19000.0 in 2022.
- On a YoY basis, Change in Account Payables climbed as much as 2650.0% in 2025 and fell as far as 15050.0% in 2025.
- IGC Pharma's Change in Account Payables stood at -$613000.0 in 2021, then jumped by 103.1% to $19000.0 in 2022, then soared by 415.79% to $98000.0 in 2023, then sank by 32.65% to $66000.0 in 2024, then slumped by 559.09% to -$303000.0 in 2025.
- Business Quant data shows IGC's Change in Account Payables at -$303000.0 in Q3 2025, $51000.0 in Q2 2025, and $45000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -303,000.00 |
| Sep 30, 2025 | -303,000.00 |
| Jun 30, 2025 | 51,000.00 |
| Jun 30, 2025 | 51,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Dec 31, 2024 | 66,000.00 |
| Dec 31, 2024 | 66,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | 126,000.00 |
| Mar 31, 2024 | 126,000.00 |
| Dec 31, 2023 | 98,000.00 |
| Dec 31, 2023 | 98,000.00 |
| Sep 30, 2023 | -123,000.00 |
| Sep 30, 2023 | -123,000.00 |
| Jun 30, 2023 | 142,000.00 |
| Jun 30, 2023 | 142,000.00 |